Discontinuing Immune Checkpoint Inhibitor–Based Therapy After Complete Response in Unresectable Hepatocellular Carcinoma: Evidence, Bias, and a Research Framework
Journal of Hepatocellular Carcinoma · 2026-10 · Volume 13 · 1-24
DOI: 10.2147/jhc.s645986 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-10. Verfasst von Yujia He und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Hospital of China Medical University, Shenyang, 110001, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
- Department of Orthopedics, The First Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
Zitieren
APA
He, Y., & Wang, Z. (2026). Discontinuing Immune Checkpoint Inhibitor–Based Therapy After Complete Response in Unresectable Hepatocellular Carcinoma: Evidence, Bias, and a Research Framework. Journal of Hepatocellular Carcinoma, Volume 13, 1-24. https://doi.org/10.2147/jhc.s645986
Vancouver
He Y, Wang Z. Discontinuing Immune Checkpoint Inhibitor–Based Therapy After Complete Response in Unresectable Hepatocellular Carcinoma: Evidence, Bias, and a Research Framework. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-24. doi:10.2147/jhc.s645986
BibTeX
@article{He2026,
author = {He, Yujia and Wang, Zhe},
title = {Discontinuing Immune Checkpoint Inhibitor–Based Therapy After Complete Response in Unresectable Hepatocellular Carcinoma: Evidence, Bias, and a Research Framework},
journal = {Journal of Hepatocellular Carcinoma},
year = {2026},
volume = {Volume 13},
pages = {1--24},
doi = {10.2147/jhc.s645986}
}
EUVIMED